A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
At a glance
- Drugs Vixotrigine (Primary)
- Indications Neuropathic pain; Trigeminal neuralgia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 10 Oct 2017 Status changed from recruiting to completed.
- 16 Feb 2015 New trial record